Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 5.91M P/E - EPS this Y - Ern Qtrly Grth -
Income -6.75M Forward P/E -0.22 EPS next Y - 50D Avg Chg -40.00%
Sales 1.11M PEG - EPS past 5Y - 200D Avg Chg -90.00%
Dividend N/A Price/Book 0.30 EPS next 5Y - 52W High Chg -98.00%
Recommedations - Quick Ratio 6.28 Shares Outstanding 6.18M 52W Low Chg 24.00%
Insider Own 0.34% ROA -89.18% Shares Float 5.98M Beta 2.50
Inst Own 10.00% ROE -183.60% Shares Shorted/Prior 81.43K/67.86K Price 0.05
Gross Margin 27.85% Profit Margin - Avg. Volume 12,481,108 Target Price -
Oper. Margin -861.43% Earnings Date - Volume 35,973,514 Change 13.26%
About Tivic Health Systems, Inc.

Tivic Health Systems Inc. operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.

Tivic Health Systems, Inc. News
11/17/24 Tivic Health Systems Third Quarter 2024 Earnings: US$0.23 loss per share (vs US$1.48 loss in 3Q 2023)
11/15/24 Tivic hits enrolment target for vagus nerve stimulation trial
11/14/24 Tivic Reports Third Quarter 2024 Financial Results and Provides Business Update
11/14/24 Enrollment Complete in Tivic Health Optimization Study for its Non-Invasive Vagus Nerve Stimulation Device
11/12/24 Tivic Health Validates European Patents in Great Britain, Germany, and France
11/07/24 Tivic Health Systems, Inc. to Report Third Quarter 2024 Financial Results on November 14
10/29/24 First Subject Enrolled in Tivic Health’s Optimization Study for its Non-Invasive Vagus Nerve Stimulation Device
10/24/24 Tivic Health CEO Jennifer Ernst to Present at New York BioFuture 2024
09/18/24 Tivic Health Gets Institutional Review Board's Approval for ncVNS Optimization Study
09/18/24 Tivic Health Receives Approval from Institutional Review Board for ncVNS Optimization Study, Readies for Enrollment
09/17/24 Tivic Health Accelerates VNS Commercial Strategy Development
09/13/24 Tivic Health Appoints Lisa Wolf as Interim Chief Financial Officer
08/14/24 Tivic Reports Second Quarter 2024 Financial Results
08/06/24 Tivic Health to Report Q2 2024 Financial Results and Corporate Update on August 14th Via Conference Call and Webcast
08/02/24 Tivic Announces 2024 Annual Meeting of Stockholders
07/23/24 Tivic Health Expands Intellectual Property Portfolio
06/18/24 Tivic Health: Christina Valauri Appointed to Board of Directors
08:00 AM Tivic Health Partners with the Feinstein Institutes to Advance its Patent-pending, Non-Invasive Cervical Vagus Nerve Stimulation; Begins Optimization of ncVNS for use in Clinical Indications
05/15/24 Tivic Reports First Quarter 2024 Financial Results and Subsequent Events
05/13/24 Tivic Health to Report Q1 2024 Financial Results and Subsequent Events on May 15th Via Conference Call and Webcast